medigraphic.com
ISSN 2594-3006 (Electronic)
ISSN 2007-1752 (Print)
Archivos de Medicina de Urgencia de México

2024, Number 2

<< Back Next >>

Arch Med Urg Mex 2024; 16 (2)

Cardiogenic shock secondary to severe anemia: volume, restriction or inotropes?

Bañuelos-Huerta R, Millan-Espinosa B

Language: Spanish
References: 19
Page: 133-139
PDF size: 442.48 Kb.


ABSTRACT

Erythrocytes and specifically hemoglobin are responsible for transporting oxygen to the tissues. However, in patients with chronic anemia, perfusion is compromised, particularly myocardial; the increase in myocardial hypoperfusion is proportional to the increase in cardiac output or by tissue oxygen consumption due to changes in the hemoglobin dissociation curve. Poor oxygen perfusion causes damage to muscle fibers, generating medium-term consequences. We speak of heart failure when there is failure to satisfy systemic demands, and cardiogenic shock is its maximum expression. Regarding controversies, we present a patient with recurrence in hospital admissions due to upper gastrointestinal bleeding secondary to Rendu-Osler-Weber Syndrome, last admission with cardiogenic shock.


REFERENCES

  1. Krzesiński P, Galas A, Gielerak G, Uziȩbło-ŻyczkowskaB. Haemodynamic Effects of Anaemia inPatients with Acute Decompensated Heart Failure.Cardiol Res Pract. 2020;2020(9371967):1–9.

  2. Carrillo Esper R, Martín Meza Márquez J, IvánFlores Rivera O, Alejandro Díaz Carrillo M, DeniseZepeda Mendoza A. Cor anémico. REVISTADE LA ASOCIACIÓN MEXICANA DE MEDICINACRÍTICA Y TERAPIA INTESSIVA [Internet]. 2015Jul;29(2):189–91. Available from: www.medigraphic.org.mx

  3. Sharma YP, Kaur N, Kasinadhuni G, Batta A, ChhabraP, Verma S, et al. Anemia in heart failure: still anunsolved enigma. Vol. 73, Springer Open. SpringerScience and Business Media Deutschland GmbH;2021. p. 1–8.

  4. Anand I, Gupta P. How I Treat Series ANEMIA How Itreat anemia in heart failure. AMERICAN SOCIETYOF HEMATOLOGY [Internet]. 2020;136(7):790–800. Available from: http://ashpublications.org/blood/article-pdf/136/7/790/1752703/bloodbld2019004004c.pdf

  5. Reddy YNV, Melenovsky V, Redfield MM, NishimuraRA, Borlaug BA. High-Output Heart Failure. J AmColl Cardiol. 2016 Aug;68(5):473–82.

  6. Anand IS. High-Output Heart Failure Revisited *. JAm Coll Cardiol. 2016 Aug;68(5):483–6.

  7. Shi R, Monnet X, Teboul JL. Parameters of fluid responsiveness.Curr Opin Crit Care [Internet]. 2020 Jun;26(3):319–26. Availablefrom: http://journals.lww.com/10.1097/MCC.0000000000000723

  8. Dereli S, Bayramoğlu A, Özer N, Cerşit S, Kaya A, Özbilen M.Evaluation of left atrial volume and function by real time three-dimensionalechocardiography in anemic patients without overtheart disease before and after anemia correction. Int J CardiovascImaging. 2019 Sep 30;35(9):1619–26.

  9. Murray E, Taylor J, Hountras P. A Case of High-Output Heart Failure.Chest. 2022 Jan 1;161(1):e23–8.

  10. Lidia Duque Estrada D, Castro Gutiérrez N, Larquin Comet J, DamiánJunco Bonet M, Betancourt Reyes G. Enfermedad de RenduOsler Weber: presentación de un caso. Revista Archivo MédicoCamagüey. 2016;20:735–43.

  11. Cherem-Kibrit M, Gomes da Silva-de Rosenzweig P, de la Vega-González F, Gutiérrez-Alvarado R, Govea-González Ó, Garduño-Hernández I, et al. Síndrome Osler-Weber-Rendu. Manejoendoscópico de un sangrado inusual: reporte de caso. Vol. 33,Revista Endoscopia. 2021 Jun.

  12. Sosa AO, Santos Moyano Z, Suárez Hormiga L, Notario NM, JaénSánchez N, López Vega J, et al. ANEMIA EN PACIENTES CONTELANGIECTASIA HEMORRÁGICAHEREDITARIA (SÍNDROMEDE RENDU OSLER WEBER). Revista Española de Cardiología[Internet]. 2013; Available from: http://www.revespcardiol.orgV-93.-ANEMIAENPACIENTESCON

  13. Kritharis A, Al-Samkari H, Kuter DJ. Hereditary hemorrhagic telangiectasia:diagnosis and management from the hematologist’sperspective. Haematologica. 2018 Sep;103(9):1433–43.

  14. Casas J, Castañeda O, Prezza P, Castillo M, Llosa L. Una PresentaciónInusual de Compromiso Hepático en Telangiectasia HemorrágicaHereditaria: Enfermedad Biliar. Rev. Gastroenterol. Perú.2009.

  15. Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, SquireIB, et al. Intravenous ferric derisomaltose in patients with heart failureand iron deficiency in the UK (IRONMAN): an investigator-initiated,prospective, randomised, open-label, blinded-endpoint trial.The Lancet (London, England) [Internet]. 2022 Nov 4;1–11. Availablefrom: http://www.ncbi.nlm.nih.gov/pubmed/36347265

  16. Donaldson RE, Seo J, Fuentes VL, Humm K. Left heart dimensionsin anemic cats and dogs before and after blood transfusion.J Vet Intern Med. 2021 Jan 1;35(1):43–50.

  17. Del M, García-Loera A. Terapia de componentes sanguíneos. GacMed Mex. 2003;139(3):S35–40.

  18. Jentzer, Jacob C, Lawler, Patrick R, Katz, Jason N, Wiley, BrandonM, Murphree, Dennis H, Bell, Malcolm R, Barsness, GregoryW, Kor, Daryl J. Red blood cell transfusion threshold and mortalityin cardiac intensive care unit patients. American Heart Journal,(2021), 24-35, 235.

  19. Vahdatpour C, Collins D, Goldberg S. Cardiogenic Shock. Vol. 8,Journal of the American Heart Association. American Heart AssociationInc.; 2019.




2020     |     www.medigraphic.com